Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 996 | 1027 | 1081 | 1032 | 1169 | 1587 |
Fund Return | -0.44% | 2.71% | 8.14% | 1.05% | 3.17% | 4.73% |
Place in category | 557 | 624 | 108 | 173 | 52 | 6 |
% in Category | 51 | 57 | 11 | 22 | 9 | 1 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Euro High Yield Class C EUR Dis | 3.33B | 7.06 | 2.54 | 3.59 | ||
Euro High Yield Class I EUR Cap | 3.33B | 7.92 | 3.08 | 4.06 | ||
Euro High Yield Class N EUR Cap | 3.33B | 6.80 | 2.24 | 3.29 | ||
Euro High Yield Class R EUR Cap | 3.33B | 7.73 | 3.12 | 4.14 | ||
Euro High Yield Class Z EUR Cap | 3.33B | 8.58 | 3.90 | 4.92 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Euro High Yield Class N EUR Cap | 3.33B | 6.80 | 2.24 | 3.29 | ||
Euro High Yield Class R EUR Cap | 3.33B | 7.73 | 3.12 | 4.14 | ||
Euro High Yield Class Z EUR Cap | 3.33B | 8.58 | 3.90 | 4.92 | ||
Euro High Yield Class C EUR Cap | 3.33B | 7.13 | 2.60 | 3.67 | ||
Euro High Yield Class C EUR Dis | 3.33B | 7.06 | 2.54 | 3.59 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Candriam Monétaire SICAV V C | FR0013113222 | 8.12 | - | - | |
Teva Pharmaceutical Finance Netherlands II B.V 4.375% | XS2406607171 | 4.18 | - | - | |
Nidda Healthcare Holding GmbH 7.5% | XS2550063478 | 2.80 | - | - | |
Lorca Telecom Bondco S.A.U. 4% | XS2240463674 | 2.57 | - | - | |
Repsol International Finance B.V. 2.5% | XS2320533131 | 2.46 | - | - |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | - | - | - |
Technical Indicators | - | - | - |
Summary | Neutral | Neutral | Neutral |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review